The Therapeutic Goods Administration (TGA) has identified medicinal cannabis advertising as a priority area for its compliance activities in FY23.
In an update to its website today, the TGA re-iterated that the public promotion of medicinal cannabis as a prescription medicine to Australian consumers is illegal and that it can inappropriately influence demand and disrupt the doctor/patient relationship.
The regulator said it will ensure compliance with the Therapeutic Goods Act 1989 across the medicinal cannabis industry and:
- Continue to engage with industry about their regulatory obligations.
- Gather and use intelligence to identify non-compliance.
- Target unlawful advertising, as well as supply where it is not in accordance with the requirements for unapproved goods.
As well as the focus on medicinal cannabis, the TGA identified the import, advertising and supply of unapproved therapeutic goods associated with Covid-19 and nicotine vaping products among its other areas of concern.
